A Research Study Examining The Use Of Duloxetine In The Prevention Of Migraine Headache - NCT00443352-19107 (Clinical Trial 164539)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy164539.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Philadelphia |
|
State:
|
|
PA |
| Zip Code: |
|
19107 |
| Conditions: |
|
Migraine |
| Purpose: |
|
This is a single-center, open-label, pilot trial to collect and evaluate data on the safety
and efficacy of duloxetine in the preventive treatment of subjects experiencing episodic
migraine headaches. Following a 28-day baseline period, qualifying subjects will be entered
into an 84-day treatment period. Subjects will be titrated over the first four weeks to a
dose of 120mg or their maximally tolerated dose (MTD). The dose adjustments will be based on
individual subject response and/or subject's tolerability. Subjects will maintain a daily
diary capturing detailed information on migraine headache days.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Subject is male or female between the ages of 18 and 65, inclusive
- Subject has an IHS diagnosis of migraine with or without aura for at least one-year
prior to screening
- Subject has experienced between 4 and 10 migraine headaches per month (inclusive)
over the past six months, with at least 24 hours separating attacks
- Subject has less than 15 total headache days per month
- Subject is able to differentiate migraine attacks from other headache types, if
applicable
- Subjects daily medications (for any indication) have remained at a stable dose for
the 60 days preceding screening
- Subject is using or agrees to use for the duration of participation a medically
acceptable form of contraception (as determined by investigator and mutually agreed
upon with patient), if female of child-bearing potential
- Subjects currently taking a single agent for the prevention of migraine must be on a
stable dose (unchanged for 2 months) prior to study entry
- Subject has negative urine pregnancy test prior to study entry, if female of
child-bearing potential
- Subject is able to understand and comply with all study requirements
- Subject provides written informed consent prior to any screening procedures being
conducted
EXCLUSION CRITERIA:
- Subjects with onset of migraine after 50 years of age
- Subjects who have been previously treated or are currently being treated with
duloxetine
- Subjects who have failed greater than 3 adequate trials of other medications the
prevention of migraine, as determined by investigator
- Subjects who have a known hypersensitivity to duloxetine or any of the inactive
ingredients
- Subject has taken any medication which has been shown to be effective for migraine
prophylaxis, on a daily basis within the 4 weeks prior to screening or at any time
during participation in the study, for any indication.
- Subjects with a history of significant drug or alcohol abuse within the past year
- Subjects with major depressive disorder or who have had a suicidal ideation in the 3
months prior to screening or have a history of attempted suicide
- Subjects who have a Beck Depression Inventory score of > 18 at screening
- Subjects who have > 0 on question number 9 of Beck Depression Inventory (Suicidal
Thoughts or Wishes question)
- Subjects who have participated in an investigational drug trial in the 30 days prior
to the screening visit
- Subjects with a current or history of a hepatic or renal disorder
- Subjects with uncontrolled narrow angle glaucoma
- Subjects who have experienced significant side effects from two different SSRI and/or
SNRI therapies, as determined by investigator
- Subjects with uncontrolled restless legs syndrome, as determined by investigator |
|
|
|
| Study is available at: |
|
Jefferson Headache Center
Philadelphia, PA 19107
United States
Primary Contact:
Meryl Latsko, MD, MPH
Email: Meryl.Latsko@jefferson.edu
Phone: 215-955-9477
Secondary Contact:
Meryl Latsko, MD, MPH
Email: meryl.latsko@jefferson.edu
Phone: 215-955-9477 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 15, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|